Paragraphs

In the next decade and a half, China and India will become two of the world’s indispensable powers—whether they rise peacefully or not. During that time, Asia will surpass the combined strength of North America and Europe in economic might, population size, and military spending.

All Publications button
1
Publication Type
Books
Publication Date
Authors
Paragraphs

President Donald Trump's ominous threat to unleash “fire and fury” on North Korea succeeded at least in garnering the attention of not only Kim Jong Un but the globe. The vague assertion of readiness to carry out a preventive attack on North Korea, even to use nuclear weapons, roiled stock markets, sent Japanese to look for bomb shelters and prompted alarmed warnings against the use of force from both foes and allies, including South Korean President Moon Jae-in. The piece is available in Chinese, English and Japanese.

All Publications button
1
Publication Type
Commentary
Publication Date
Journal Publisher
Dun Jiao Du
Authors
Daniel C. Sneider
-

Abstract: Mainland China has undergone a rapid development of nuclear power during the last two decades. The reactors under construction or soon to be constructed there include some of the world's most advanced models. While the average age of the workforce in China’s nuclear industry is still in the early 30s, China has already become largely self-sufficient in reactor design and construction, as well as other aspects of the fuel cycle. They have made full use of western technology while adapting and improving it, and now have set up a “go global” policy for exporting nuclear technology including heavy components to the rest of the world that may seem to be a strong competition to the US nuclear power industry. 

The speaker has led some two-way educational exchange programs with China during the last 20 years, including training about 20 Chinese nuclear engineers at the University of Michigan (UM), and taking over 100 UM students to China’s nuclear power construction sites and research institutions as visitors or interns. He will share his observation and thoughts with the audience on why we should continue to collaborate with China in nuclear engineering education and research, and how such collaboration can be a win-win deal for both countries in terms of global nuclear safety, technological advancement and economics. 
 

Speaker Bio: Dr. Lumin Wang came to US from China in 1982 and received his PhD in Materials Science from the University of Wisconsin-Madison in 1988. He is a professor in the Department of Nuclear Engineering & Radiological Sciences and the Department of Materials Science & Engineering at the University of Michigan, Ann Arbor (UM). He worked at Argonne National Laboratory and University of New Mexico before joining UM in 1997. Professor Wang’s main research interests are on radiation tolerance of nuclear engineering materials and ion beam modification of materials. Professor Wang has published more than 400 SCI indexed research papers with an h-index above 50. Professor Wang has been serving on the International Committee of American Nuclear Society (ANS) since 2010. He has taken over 100 UM students to China to observe the development of nuclear power there seven summers in a row since 2010. Professor Wang was named as an outstanding nuclear engineering professor in 2008 and an international ambassador in 2013 by UM’s college of engineering. 

Lumin Wang Professor, Dept. of Nuclear Engineering & Radiological Sciences University of Michigan
Seminars
Authors
News Type
News
Date
Paragraphs

On July 21, SCPKU was the site of a seminar entitled “Medical Big Data Application Assessment and Safeguards.”  Co-sponsored by the Chinese Health Information Association (CHIA) and the China National Health Development Research Center of the People’s Republic of China (NHDRC), this event was the group’s second seminar focused on this topic which gathered over 80 participants including leaders from CHIA, NHDRC, local members of the Health and Family Planning Commission, and academic representatives from universities, medical institutes and pharmaceutical companies. The seminar concentrated on the fusion of medical big data and health care services, decision outcomes, as well as deployment by the State Council and National Health and Family Planning Commission of the People’s Republic of China (NHFPC).

 

Following NHDRC Director Wei Fu’s opening remarks, Xuefeng Ling, SCPKU Faculty Fellow, Principal Investigator of the Translational Medical Program at Stanford University and co-founder of HBI Solutions, gave a talk on the application of medical big data in decision support. Dr. Ling introduced big data based business intelligent solutions for health management platforms that hold electronic medical records as structured data. Big data based business intelligent solutions have been shown to yield better performance than traditional unstructured solutions in numerous cases including situational awareness, population approach, and risk information.

 

University of California-Riverside Bioengineering Associate Professor Jiayu Liao followed with a presentation on Chinese medicine and its contribution to medical big data. Dr. Liao cited the latest clinically validated immunosuppressant inspired by Chinese medicine which is cheaper and more effective than its predecessors.  He also highlighted the first reported Non-peptide GLP-1R Agonist with in vivo efficacy and a new fluorescence resonance energy transfer technique, both of which are based on Chinese medicine.

 

Harvard Professor of Statistics and Director of Graduate Studies Jun Liu, West China Hospital Vice President and Professor Wei Zhang, and Taizhou Pharmaceutical High-Tech District Health Bureau Director Tao Zhang separately presented on medical big data applications in medical management and service, medical service evaluation and applications based on diagnosis related groups, and Taizhou’s demand and practices.  NHFPC Associate Director and CHIA Chairman Xiaotao Jin and Chinese Academy of Chinese Medical Sciences (CACMS) and Academicians of Chinese Academy of Engineering (CAE) Dean Boli Zhang also presented.

 

Dr. Ling and Health and Development Center Professor Long Cheng closed the seminar with a discussion focused on early investigations into a medical big data application evaluation index system and an international medical big data human resources development cooperation plan. 

Hero Image
bruce ling scpku event
Experts discuss medical big data application assessment and safeguards at SCPKU, July 21, 2017.
Stanford University
All News button
1
News Type
News
Date
Paragraphs

On March 30 and 31, 2017, Stanford held two events at SCPKU featuring the latest developments in quantitative finance and financial technology. 

On March 30, the university co-organized with SCPKU, Tsinghua University’s School of Economics and Management and the Department of Mathematics, and Peking University’s  (PKU) Guanghua School of Management and Department of Financial Mathematics, a conference featuring new developments in quantitative finance and risk management with a particular emphasis on trade execution, financial technology, data analysis, and insurance.   This event was the third biennial conference following previous ones at PKU in 2013 and Tsinghua in 2015. Following opening remarks by Stanford Professor of Statistics and Director of Stanford's Financial and Risk Modeling Institute (FARM) Tze Lai, experts from academia and industry including J.P. Morgan, PKU, Tsinghua, Renmin University of China, Daokoudai and the Southwest University of Finance and Economics in Chengdu, shared the latest developments in a wide spectrum of quantitative finance topics ranging from conditional quasi-Monte Carlo methods to China’s peer-to-peer lending market. 

FARM and SCPKU also co-organized a forum on financial technology and portfolio management on March 31.  Due to advances in artificial intelligence and big data technologies, the financial industry is facing tremendous pressure to develop and implement solutions yielding improved operational efficiencies.  This forum convened distinguished academic and industry speakers from quantitative trading, wealth management, asset management, financial consulting, and credit rating firms and agencies to explore the current development and future for financial technology and portfolio management.

Hero Image
822898726
Stanford Professor of Statistics Tze Lai (center, seated) and financial forum speakers at SCPKU.
Stanford University
All News button
1
Authors
News Type
News
Date
Paragraphs

Stanford’s Center for Innovative Study Design, with co-sponsors including the Stanford Center at Peking University (SCPKU), the International Society for Biopharmaceutical Statistics and Tsinghua University’s Center for Hospital Management, held a Forum on Regulatory Science and Biomedical Innovations at SCPKU on March 22, 2017. The event gathered more than 60 leaders from the Chinese Food and Drug Administrations (CFDA), Chinese Association of Preventive Medical (CAPM), universities, professional organizations, and R&D experts from domestic and international biopharmaceutical companies.

Over the last decade, significant progress has been made in medical research, disease treatment and general health and well-being.  The Chinese government has called out innovation as a major national strategy to achieve sustainable growth.  At the same time, to address public health and safety, the country’s regulatory agencies are tasked with implementing relevant laws to ensure the safety and efficacy of new products and services before they’re available to the public. The ability of regulatory agencies, laws and regulations to promote innovation while protecting public health is an important research question.  This forum at SCPKU was designed to facilitate a high-level discussion on this topic by scholars from academia from both China and the US, CFDA leaders, and R&D experts from biomedical industries.

The forum was structured with four keynote talks and two panel discussions. Dr. Ruiyi He, the Chief Scientist at the Center for Drug Evaluation of CFDA, delivered a speech on CFDA’s plan to enhance regulations on drug evaluation to promote the development of new drugs. He highlighted some major initiatives to align with ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use).  In June 2017, China became a member of ICH. Dr. Dechao Yu, founder and CEO of the Innovent Biologics, Inc., gave a talk on opportunities and challenges in innovative biologics in China. He shared his experience in developing Oncorine and Conbercept in China and the needs for regulation reform for innovative new drug applications. Professor Jiqian Fang from Sun Yat-Sen University reviewed the development of the CFDA in the past two decades and called for open, transparent and academic participation in innovative development of drug review and approval regulations. Professor Baoyan Liu, Vice President of the Chinese Academy of Chinese Medicine Sciences, presented innovations in Chinese medicine (CM) using clinical trials and big data, and the regulatory needs tailored for the sciences of CM.

The two panel discussions were focused on the challenges and opportunities in evaluating the safety and efficacy of innovative biomedical products and collaboration in biomedical innovations. Panelists included a CFDA division director, CFDA biostatisticians, several members of the CFDA advisory committee, a vice president of CAPM, and CEOs of several biomedical startups in China.

Attendees were able to exchange ideas in an open and fair environment and many expressed interest in joining future SCPKU-based forums and workshops on this topic.  Forum participants drew the following conclusions:

 

·   Regulatory science plays an important role in promoting and supporting biomedical innovations.

·   Regulatory reforms should be open, transparent, science-driven, and in alignment with international standards.

·   Low-quality generic drugs should not be supported.

·   Regulatory agencies, academics, and the biopharmaceutical industry should work together on developing science-based policies to make effective, safe and affordable drugs for Chinese patients.

 

The Center for Innovative Study Design also held a Workshop on Innovative Statistical Methods in Precision Medicine and Big Data at SCPKU on March 23, 2017. Twelve statisticians from the Chinese FDA, Chinese universities and US universities presented their research on advanced clinical trial design, statistical innovations in big data, and applications of machine learning in biomedical data science. More than 60 attendees from local universities (both faculty and graduate students), government, and pharmaceutical companies joined the workshop and had many insightful discussions.

 

 

Hero Image
Ying Lu SCPKU Forum Mar 22 2017
Dr. Jie Chen, International Society for Biopharmaceutical Statistics (L), and Ying Lu, Professor of Biomedical Data Science and Co-Director of the Center for Innovative Study Design at Stanford University (R), speak during SCPKU forum March 2017.
Dr. Jie Chen, International Society for Biopharmaceutical Statistics
All News button
1
Paragraphs

The most dangerous impact of North Korea’s long-range missile test this past week may not have been the one in the Sea of Japan, felt in Washington, Seoul and Tokyo. It was in Moscow where Chinese leader Xi Jinping and Russian President Vladimir Putin locked arms in a united front on how to respond to the growing North Korea crisis. The target of this front was not, however, North Korea. It was the United States, who the Sino-Russian axis accused of pursuing a military “buildup” in the region.

All Publications button
1
Publication Type
Commentary
Publication Date
Journal Publisher
Tokyo Business Today
Authors
Daniel C. Sneider
News Type
Commentary
Date
Paragraphs

South Korean President Moon Jae-in and U.S. President Donald Trump recently held a summit in Washington, their first face-to-face meeting in a time of heightened tensions on the Korean Peninsula. Experts from the Shorenstein Asia-Pacific Research Center offered insights in a series of publications and press interviews.

In advance of the summit, William J. Perry Fellow Kathleen Stephens spoke on Bloomberg television about the challenges facing the United States and South Korea, and how those challenges would be prioritized during the bilateral meeting.

Moon would be bringing the message that the U.S.-South Korea alliance is a “strong one and that he remains committed to it,” and that, “only by working transparently and closely together” could the two countries address areas of concern, Stephens said.

“Only when Washington and Seoul are able to talk very frankly to each other and come up with a coordinated plan do we have any chance of making some progress on North Korea,” she added.

Stephens joined the program from Seoul, where a group of Shorenstein APARC faculty and fellows participated in a public seminar and the Korea-U.S. West Coast Strategic Forum, a biannual conference that seeks to foster dialogue about issues affecting the Korean Peninsula and the U.S.-South Korea alliance.

The seminar, held in conjunction with The Sejong Institute, received press coverage; such articles can be read on the Voice of America website (in Korean) and Sisa Journal website (in Korean).

In an analysis piece for Tokyo Business Today, Associate Director for Research Daniel Sneider assessed the outcomes of the summit between Moon and Trump, suggesting that their meeting was satisfactory – without signs of major discord.

“For the most part, this display of calculated pragmatism worked well. There was no visible daylight between the two leaders over how to handle the North and THAAD totally disappeared from the summit talk, at least in public and in the joint statement issued by the two governments.”

The summit, however, may prove to be a “temporary gain,” Sneider added. “Beneath the smiles, there was plenty of evidence of the gaps, and even the tensions, that exist between a progressive government in Seoul, one that echoes the views of its ideological predecessors of a decade ago, and a nationalist, conservative regime in Washington.”

Read the piece in English and Japanese.

Days after the summit, North Korea test-launched an intercontinental ballistic missile (ICBM), which the United States and South Korea followed by hosting joint military exercises.

Stephens spoke on WBUR radio about the ICBM test launch and the initial reactions of the Trump administration.

“If [President Trump’s] agenda is to take stronger defensive measures against North Korea, I think he will find strong partners in Japan and South Korea,” she said, noting that other measures, such as diplomacy and economic sanctions, have also been used to affect pressure on the regime.

Responding to a question about China’s relationship with North Korea, Stephens said Beijing has not exhausted all possible tools in its efforts to persuade Pyongyang to slow or abandon its nuclear and missile activities. This is because China fears a collapse of the regime and “takes a long view” in its calculus, she said.

This news item has been updated.

Hero Image
trump moon summit
U.S. President Donald Trump and South Korean President Moon Jae-in come out from the Oval Office to deliver joint statements in the Rose Garden at the White House on June 30, 2017, in Washington, DC.
Getty Images - Alex Wong
All News button
1
Subscribe to China